Update on the treatment of Pseudomonas aeruginosa pneumonia (Q37516904)

20 August 2017

1 reference

title

Update on the treatment of Pseudomonas aeruginosa pneumonia (English)

1 reference

20 August 2017

0 references

Pseudomonas aeruginosa

0 references

author name string

Ali A El Solh

series ordinal

1

1 reference

20 August 2017

Ahmad Alhajhusain

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

11 June 2009

1 reference

Journal of Antimicrobial Chemotherapy

20 August 2017

published in

1 reference

20 August 2017

volume

64

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

229-238

1 reference

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Pathogen-host interactions in Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Treatment options for multidrug-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Previous endotracheal aspirate allows guiding the initial treatment of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

The importance of addressing multidrug resistance and not assuming single-drug resistance in case-control studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a Combination Antibiogram

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy*

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Cure of persistent, post-appendectomy Klebsiella pneumoniae septicaemia with continuous intravenous administration of meropenem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Ventilator-associated pneumonia due to colistin susceptible-only microorganisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Nephrotoxicity of intravenous colistin: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Toxicity after prolonged (more than four weeks) administration of intravenous colistin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Administration of antibiotics via the respiratory tract as monotherapy for pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Modulation of lung epithelial functions by Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP201

21 January 2018

Identifiers

DOI

10.1093/JAC/DKP201

1 reference

20 August 2017

1 reference